<DOC>
	<DOCNO>NCT02797951</DOCNO>
	<brief_summary>The main purpose study ass long-term safety tolerability galcanezumab administer monthly participant episodic chronic cluster headache complete study I5Q-MC-CGAL ( NCT02397473 ) study I5Q-MC-CGAM ( NCT02438826 ) .</brief_summary>
	<brief_title>A Study LY2951742 ( Galcanezumab ) Participants With Cluster Headache</brief_title>
	<detailed_description />
	<mesh_term>Headache</mesh_term>
	<mesh_term>Cluster Headache</mesh_term>
	<criteria>Participants participate complete either study CGAL study CGAM . Investigator judge participant reliable follow study procedure , keep study visit , compliant study requirement . Current enrollment discontinuation within last 30 day , clinical trial involve investigational drug device ( exception Study CGAL Study CGAM ) . Current use prior exposure calcitoningenerelated peptide ( CGRP ) antibody , antibody CGRP receptor , antibody nerve growth factor ( NGF ) ( exception Study CGAL Study CGAM ) . A history migraine variant could implicate could confuse ischemia . Known hypersensitivity multiple drug , monoclonal antibody therapeutic protein . A history presence medical illness indicate medical problem would preclude study participation . Evidence significant active unstable psychiatric disease , opinion investigator . Women pregnant nursing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>cluster headache</keyword>
	<keyword>headache</keyword>
	<keyword>brain disease</keyword>
	<keyword>central nervous system disease</keyword>
	<keyword>headache disorder</keyword>
	<keyword>headache disorder , primary</keyword>
	<keyword>nervous system disease</keyword>
	<keyword>neurologic manifestation</keyword>
	<keyword>pain</keyword>
	<keyword>trigeminal autonomic cephalalgia</keyword>
</DOC>